{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"17.6","value":"8.3"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"35.7","value":"7.1"},{"groupId":"OG002","lowerLimit":"0.1","upperLimit":"35.7","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"35"}],"units":"Participants"}],"description":"Median total number of CD34+ cells collected during apheresis as measured by a central lab.","dispersionType":"Full Range","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population. Samples from two participants were not analyzed by the central lab.","reportingStatus":"POSTED","timeFrame":"Days 5-8","title":"Median Cumulative Number of CD34+ Cells Collected During Apheresis","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"CD34+ cells (*10^6 / kg)"}